9
1
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T6594 |
MNS
|
Syk; Src; p97 | Angiogenesis; Tyrosine Kinase/Adaptors; Ubiquitination |
MNS 是一种酪氨酸激酶抑制剂和广谱抗血小板药物,是一种 β-硝基苯乙烯衍生物。它完全抑制 U46619 (IC50:2.1 μM)、ADP (IC50:4.1 μM)、花生四烯酸 (IC50:5.8 μM)、胶原 (IC50:7.0 μM)和凝血酶 (IC50:12.7 μM)诱导的血小板聚集,并抑制 Src (IC50:27.3 μM)、Syk (IC50:2.8 μM) 和 FAK (IC50:97.6 μM)。 | |||
T8719 |
SC99
|
Apoptosis; JAK; STAT | Angiogenesis; Apoptosis; Chromatin/Epigenetic; JAK/STAT signaling; Stem Cells |
SC99 是一种口服有效选择性STAT3抑制剂,靶向 JAK2-STAT3 途径,抑制血小板活化和聚集,有抗骨髓瘤和抗血栓活性。它结合在 JAK2 的 ATP 结合袋中,抑制 JAK2 和 STAT3 的磷酸化。 | |||
T29097 |
VAS 3947
VA-S3947,VA S3947,VAS3947 |
Apoptosis; NADPH-oxidase | Apoptosis; Immunology/Inflammation |
VAS 3947 是一种特异的 NADPH 氧化酶 (NOX) 抑制剂。VAS 3947具有强大的抗血小板作用, 通过 UPR 激活,主要由于蛋白质聚集和错误折叠,独立于抗 NOX 活性诱导细胞凋亡。 | |||
T0179 |
Ticagrelor
替格瑞洛,替卡格雷,AR-C 126532XX,AZD6140 |
P450; P2Y Receptor | GPCR/G Protein; Metabolism; Neuroscience |
Ticagrelor (AR-C 126532XX) (AZD6140) 是可逆的,可口服的 P2Y12受体拮抗剂,可抑制血小板聚集。 | |||
T28044 | MIPS-9922 | ||
MIPS-9922 is a potent and selective PI3Kβ inhibitor with antiplatelet activity. MIPS-9922 inhibited integrin αIIbβ3 activation and αIIbβ3 dependent platelet adhesion to immobilized vWF under high shear. MIPS-9922 also potently inhibited ADP-induced washe | |||
T71254 |
Clopidogrel HCl
|
||
Clopidogrel HCl is the salt form of Clopidogrel (free base), an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. | |||
T70865 |
BMY-42393
|
||
BMY-42393 is orally active and selective platelet aggregation inhibitor. BMY-42393 is also a prostacyclin partial agonist that inhibited ADP, collagen and thrombin-induced platelet aggregation (IC50 range 0.3 - 2.0 microM). BMY-42393 stimulated platelet adenylate cyclase activity (EC50 = 25 nM). Platelets treated with BMY 42393 showed an elevation of cAMP levels and activation of cAMP-dependent protein kinase. BMY 42393 also inhibited thrombin-induced elevation of intracellular free calcium. B... | |||
T36236 |
5-cis Carbaprostacyclin
|
||
5-cis Carbaprostacyclin is a stable analog of PGI2 and an isomer of carbaprostacyclin. It is a weak inhibitor of human platelet aggregation with an IC50 of 2.8 μM compared to 0.3 μM for carbaprostacyclin. 5-cis Carbaprostacyclin is a much weaker effector of rabbit mesenteric artery relaxation with an EC50 of 104 μM compared to 5.9 μM for carbaprostacyclin. It even antagonizes the adenylate cyclase activation induced by carbaprostacyclin. | |||
T26657 |
AR-H067637
|
||
AR-H067637 is a rapid-binding, reversible and potent (inhibition constant K(i) = 2-4 nM), competitive inhibitor of thrombin, as well as of thrombin bound to fibrin (clot-bound thrombin) or to thrombomodulin. The total amount of free thrombin generated in |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPH-00213 |
Disintegrin batroxostatin Protein, Bothrops atrox, Recombinant (His & Myc)
Platelet aggregation activation <... |
Bothrops atrox | E. coli |
Inhibits fibrinogen interaction with platelets. Acts by binding to the glycoprotein IIb-IIIa receptor (ITGA2B/ITGB3) on the platelet surface and inhibits aggregation induced by ADP, thrombin, platelet-activating factor and collagen. Also inhibits T24 and SK-Mel-28 cell adhesion to fibronectin with IC(50) of 4.4 uM and 33 nM, respectively. Disintegrin batroxostatin Protein, Bothrops atrox, Recombinant (His & Myc) is expressed in E. coli expression system with N-10xHis and C-Myc tag. The predicted... |